High mobility group box 1 (
HMGB1) was recently shown to be an important extracellular mediator of severe vascular inflammatory disease,
sepsis.
Lysozyme protects us from the ever-present danger of
bacterial infection and binds to bacterial
lipopolysaccharide (LPS) with a high affinity. Here, we show, for the first time, the anti-septic effects of
lysozyme in HMGB1-mediated inflammatory responses in vitro and in vivo. The data showed that
lysozyme posttreatment suppressed LPS-mediated release of
HMGB1 and HMGB1-mediated cytoskeletal rearrangement.
Lysozyme also inhibited HMGB1-mediated hyperpermeability and leukocyte migration in human endothelial cells. In addition,
lysozyme inhibited the HMGB1-mediated activation of Akt, nuclear factor-κB (NF-κB), extracellular regulated
kinases (ERK) 1/2 and production of
interleukin (IL)-1β,
IL-6,
tumor necrosis factor-α (TNF-α), and
chemoattractant protein-1 (MCP-1) in HUVECs. Furthermore,
lysozyme reduced the cecal
ligation and
puncture (CLP)-induced release of
HMGB1, migration of leukocytes, septic mortality, and pulmonary damage in mice. Collectively, these results suggest
lysozyme as a candidate therapeutic agent for the treatment of vascular inflammatory diseases via inhibition of the
HMGB1 signaling pathway.